ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL376359
CHEMBL376359
Compound Name ALOGLIPTIN
ChEMBL Synonyms SYR-322 | ALOGLIPTIN BENZOATE | NESINA | ALOGLIPTIN | Alogliptin TFA
Max Phase 4 (Approved)
Trade Names NESINA
Molecular Formula C18H21N5O2

Additional synonyms for CHEMBL376359 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(Cc3ccccc3C#N)C1=O
Standard InChI InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23 ...
Download InChI
Standard InChI Key ZSBOMTDTBDDKMP-OAHLLOKOSA-N

Sources

  • British National Formulary
  • Orange Book
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL376359

Molecule Features

CHEMBL376359 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Dipeptidyl peptidase IV inhibitor Dipeptidyl peptidase IV DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
DIABETES MELLITUSD003920EFO:0000400DIABETES MELLITUS4ATC
ClinicalTrials
DIABETES MELLITUS, TYPE 2D003924EFO:0001360TYPE II DIABETES MELLITUS4DailyMed
DailyMed
ClinicalTrials
ClinicalTrials
DailyMed

Clinical Data

ClinicalTrials.gov ALOGLIPTIN
The Cochrane Collaboration ALOGLIPTIN

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL376359. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL284 Dipeptidyl peptidase IV Homo sapiens 1.000
CHEMBL240 HERG Homo sapiens 0.338

10uM


ChEMBL_ID Target Name Organism Score
CHEMBL284 Dipeptidyl peptidase IV Homo sapiens 1.000
CHEMBL4683 Fibroblast activation protein alpha Homo sapiens 0.999
CHEMBL240 HERG Homo sapiens 0.870
CHEMBL231 Histamine H1 receptor Homo sapiens 0.542
CHEMBL273 Serotonin 1a (5-HT1a) receptor Rattus norvegicus 0.411

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
339.4 339.1695 1.27 3 93.66 BASE


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
5 1 0 7 2 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
- 9.89 1.62 -.71 1 25 0.9

Structural Alerts

There are no structural alerts for CHEMBL376359

Compound Cross References

ATC A - ALIMENTARY TRACT AND METABOLISM
A10 - DRUGS USED IN DIABETES
A10B - BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BH - Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10BH04 - alogliptin

ChemSpider ChemSpider:ZSBOMTDTBDDKMP-OAHLLOKOSA-N
DailyMed alogliptin benzoate
Wikipedia Alogliptin

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL376359



ACToR 850649-61-5
BindingDB 16285
Brenda 38639
ChEBI 72323
DrugBank DB06203
DrugCentral 4340
eMolecules 31229135
EPA CompTox Dashboard DTXSID90234130
FDA SRS JHC049LO86
Guide to Pharmacology 6319
IBM Patent System 4BAB1F190189E58A99E2EC4092194DBD
MolPort MolPort-005-933-065
Nikkaji J2.587.439K
PDBe T22
PubChem 11450633
PubChem: Thomson Pharma 16549582
Selleck alogliptin-syr-322
SureChEMBL SCHEMBL121028
ZINC ZINC000014961096

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/ZSBOMTDTBDDKMP-OAHLLOKOSA-N spacer
spacer